ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
ReShape Lifesciences (Nasdaq: RSLS) announced its inaugural Lap-Band® Surgeon Summit, scheduled for August 1-3, 2025, in Nashville, Tennessee. The summit will be directed by Dr. Christine Ren-Fielding, Professor of Surgery at NYU Grossman School of Medicine, and will host over 20 leading Lap-Band® surgeons.
The event will focus on the benefits of both the original Lap-Band® and the next-generation Lap-Band® 2.0 FLEX, exploring the role of GLP-1s in patient care and strategies for patient education. The company has reported positive early feedback from the limited U.S. market release of the Lap-Band® 2.0 FLEX, which features self-adjusting technology designed to work alongside medical therapies like GLP-1s.
ReShape Lifesciences (Nasdaq: RSLS) ha annunciato il suo primo Lap-Band® Surgeon Summit, previsto dal 1° al 3 agosto 2025 a Nashville, Tennessee. Il summit sarà diretto dalla Dott.ssa Christine Ren-Fielding, Professore di Chirurgia presso la NYU Grossman School of Medicine, e vedrà la partecipazione di oltre 20 tra i più importanti chirurghi specializzati in Lap-Band®.
L'evento si concentrerà sui vantaggi sia del Lap-Band® originale sia della nuova generazione Lap-Band® 2.0 FLEX, approfondendo il ruolo degli GLP-1 nella cura dei pazienti e le strategie per l'educazione del paziente. L'azienda ha riportato riscontri positivi iniziali dalla limitata commercializzazione negli Stati Uniti del Lap-Band® 2.0 FLEX, che integra una tecnologia di auto-regolazione pensata per affiancare terapie mediche come gli GLP-1.
ReShape Lifesciences (Nasdaq: RSLS) anunció su primera Cumbre de Cirujanos Lap-Band®, programada del 1 al 3 de agosto de 2025 en Nashville, Tennessee. La cumbre estará dirigida por la Dra. Christine Ren-Fielding, profesora de cirugía en la NYU Grossman School of Medicine, y reunirá a más de 20 destacados cirujanos especializados en Lap-Band®.
El evento se centrará en los beneficios tanto del Lap-Band® original como de la nueva generación Lap-Band® 2.0 FLEX, explorando el papel de los GLP-1 en la atención al paciente y las estrategias para la educación del paciente. La compañía ha informado comentarios positivos iniciales tras el lanzamiento limitado en el mercado estadounidense del Lap-Band® 2.0 FLEX, que cuenta con tecnología de autoajuste diseñada para complementarse con terapias médicas como los GLP-1.
ReShape Lifesciences (나스닥: RSLS)는 2025년 8월 1일부터 3일까지 테네시주 내슈빌에서 개최되는 첫 번째 Lap-Band® 외과의사 서밋을 발표했습니다. 이 서밋은 NYU Grossman 의과대학의 외과 교수인 Dr. Christine Ren-Fielding가 주도하며 20명 이상의 주요 Lap-Band® 외과의사들이 참석할 예정입니다.
이번 행사는 원조 Lap-Band®와 차세대 Lap-Band® 2.0 FLEX의 이점을 중심으로 GLP-1이 환자 치료에서 하는 역할과 환자 교육 전략을 탐구할 예정입니다. 회사는 GLP-1과 같은 의료 치료와 함께 작동하도록 설계된 자동 조절 기술을 특징으로 하는 Lap-Band® 2.0 FLEX의 미국 내 제한적 시장 출시에서 긍정적인 초기 반응을 보고했습니다.
ReShape Lifesciences (Nasdaq : RSLS) a annoncé son tout premier Lap-Band® Surgeon Summit, prévu du 1er au 3 août 2025 à Nashville, Tennessee. Le sommet sera dirigé par la Dr Christine Ren-Fielding, professeure de chirurgie à la NYU Grossman School of Medicine, et réunira plus de 20 chirurgiens de premier plan spécialisés dans le Lap-Band®.
L'événement mettra l'accent sur les avantages du Lap-Band® original ainsi que sur ceux de la nouvelle génération Lap-Band® 2.0 FLEX, en explorant le rôle des GLP-1 dans la prise en charge des patients et les stratégies d'éducation des patients. L'entreprise a rapporté des retours positifs précoces suite au lancement limité sur le marché américain du Lap-Band® 2.0 FLEX, qui intègre une technologie d'auto-ajustement conçue pour fonctionner en complément des thérapies médicales telles que les GLP-1.
ReShape Lifesciences (Nasdaq: RSLS) gab seinen ersten Lap-Band® Surgeon Summit bekannt, der vom 1. bis 3. August 2025 in Nashville, Tennessee, stattfinden wird. Der Gipfel wird von Dr. Christine Ren-Fielding, Professorin für Chirurgie an der NYU Grossman School of Medicine, geleitet und bringt über 20 führende Lap-Band®-Chirurgen zusammen.
Die Veranstaltung konzentriert sich auf die Vorteile sowohl des ursprünglichen Lap-Band® als auch der nächsten Generation Lap-Band® 2.0 FLEX und beleuchtet die Rolle von GLP-1 bei der Patientenversorgung sowie Strategien zur Patientenaufklärung. Das Unternehmen hat positives erstes Feedback aus der begrenzten Markteinführung des Lap-Band® 2.0 FLEX in den USA erhalten, das eine selbstregulierende Technologie beinhaltet, die in Kombination mit medizinischen Therapien wie GLP-1s arbeitet.
- None.
- None.
Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025
IRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host its inaugural Lap-Band® Surgeon Summit, taking place August 1-3, 2025 in Nashville, Tennessee. Dr. Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of the NYU Langone Weight Management Program, and Chief of the Division of Bariatric Surgeons, will direct the Summit, where she and other faculty will present to over 20 leading Lap-Band® surgeons.
“Our inaugural Lap-Band® Surgeon Summit brings together leading bariatric surgeons and underscores our continued commitment to growing the Lap-Band® franchise,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “We are especially honored to have Dr. Ren-Fielding, one of the foremost champions of the Lap-Band®, share her invaluable insights at this milestone event. Our goal is to collaborate closely with these experienced surgeons to continue enhancing patient outcomes and expanding access to this vital weight management tool.”
The Summit will focus on the benefits of both the original Lap-Band® and the next-generation Lap-Band® 2.0 FLEX, the evolving role of GLP-1s in comprehensive patient care, and effective strategies for educating and engaging Lap-Band® patients. Notably, ReShape Lifesciences has already seen overwhelmingly positive early feedback from the limited U.S. market release of the Lap-Band® 2.0 FLEX.
“As one of the first surgeons trained on the Lap-Band® over two decades ago, I’ve seen firsthand its value as a safe, adjustable, and durable weight loss solution,” stated Dr. Ren-Fielding. “Today, with the rise of GLP-1 medications and growing patient openness to combination therapies, we have an incredible opportunity to enhance outcomes. The new Lap-Band® 2.0 FLEX represents a major advancement, its self-adjusting technology addresses past challenges while working seamlessly alongside medical therapies like GLP-1s.”
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include the statements that our goal is to continue to enhance patient outcomes and expand access to the Lap-Band. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
Dr. Ren-Fielding receives consulting and other compensation from ReShape Lifesciences. Her views are her own and do not represent an endorsement by NYU Langone Health.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
FAQ
When and where is ReShape Lifesciences (RSLS) hosting its Lap-Band® Surgeon Summit?
Who will direct the RSLS Lap-Band® Surgeon Summit 2025?
What topics will be covered at the 2025 RSLS Lap-Band® Surgeon Summit?
What is new about the Lap-Band® 2.0 FLEX from ReShape Lifesciences?
